Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease
- PMID: 32832510
- PMCID: PMC7423537
- DOI: 10.21037/hbsn.2019.11.24
Probiotics and synbiotics targeting the intestinal microbiome attenuate non-alcoholic fatty liver disease
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2019.11.24). LV reports in addition, LV has a patent 2017101478 issued. LV and JDH participate in the Medlab Clinical’s research on probiotics.
Figures
Comment on
- 
  
  Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.Am J Clin Nutr. 2019 Jul 1;110(1):139-149. doi: 10.1093/ajcn/nqz042. Am J Clin Nutr. 2019. PMID: 31124558 Free PMC article.
References
Publication types
LinkOut - more resources
- Full Text Sources
 
         
              